Drug intelligence / Profile preview

N-Propargyl-1(S)-Aminoindan

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules

Overview

N-Propargyl-1(S)-Aminoindan is a small molecule belonging to the class of indanes. It is the S-enantiomer of N-propargyl-1-aminoindan and a structural analog related to rasagiline, which is the R-enantiomer. Unlike rasagiline, which is a potent and selective irreversible inhibitor of monoamine oxidase B (MAO-B) used in Parkinson’s disease therapy, the S-enantiomer (N-Propargyl-1(S)-Aminoindan) exhibits very weak and poorly selective MAO inhibitory activity. The compound has been studied experimentally but has not advanced into clinical development or approval for any indication[2][4]. Its mechanism involves weak inhibition of amine oxidase [flavin-containing] B[4].

Other names: (1S)-2,3-Dihydro-N-2-propyn-1-yl-1H-inden-1-amine

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on N-Propargyl-1(S)-Aminoindan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-Propargyl-1(S)-Aminoindan.

Explore the full profile